Medical/Pharmaceuticals
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors * K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China * Antengene r...
2026-06-22 08:30
3808
Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand
SYDNEY and AUCKLAND, New Zealand, June 22, 2026 /PRNewswire/ -- Murj®, a cardiac device management software company, today announced its official expansion into the Australian market alongside broader availability for New Zealand. Following its exhibition at the recent CSANZ / HRS Advances in Pac...
2026-06-22 07:00
2912
Seoul National University Hospital to Expand Global K-Bio Collaboration at BIO USA 2026
SAN DIEGO and SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's global presence and international collaboration at BIO International Convention 2026 (BIO USA), the world's largest biotechnology industry even...
2026-06-19 23:00
4420
INTCO Medical Showcases Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy Solutions at WHX Miami 2026
MIAMI, June 19, 2026 /PRNewswire/ -- INTCO Medical
2026-06-19 16:38
6135
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in c...
2026-06-18 23:00
4791
Frost & Sullivan Identifies Virtual Healthcare Assistants as a Transformational Force in Healthcare Delivery
New analysis highlights significant growth opportunities in patient- and clinician-facing AI assistants as healthcare organizations seek to improve efficiency, patient engagement, and care outcomes LONDON, June 18, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Innovations and Growth O...
2026-06-18 21:07
3704
ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing
ZEISS Medical Technology and Envision Health Technologies will collaborate to advance the next generation of patient-accessible, software-driven visual function testing while maintaining a science-first approach to glaucoma care. JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technolo...
2026-06-18 21:00
4016
Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies
* 90% Female Prevalence: PBC is a critical women's health issue, yet symptoms like crushing fatigue and relentless itching are frequently misdiagnosed as menopause or stress. * 30-Year Innovation Gap: This new class of therapy is the first major breakthrough in three decades for the 40% of pa...
2026-06-18 17:03
4069
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the Europe...
2026-06-18 12:57
6747
AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial
SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 cl...
2026-06-18 10:00
4380
ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units
JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that the company held a signing ceremony with the Aier Eye Hospital Group, entering into a strategic agreement for the purchase and installation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier Ey...
2026-06-18 08:49
5102
Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon
OXFORD, England, June 18, 2026 /PRNewswire/ -- Tinnitus Quest
2026-06-18 03:55
4415
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration wit...
2026-06-17 21:00
6558
FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin
Major regulatory milestone paves the way for commercialization and marks first step toward broader CxM biomarker sensing strategy BASEL, Switzerland, June 17, 2026 /PRNewswire/ -- FiberSense AG ("FiberSense") today announced that the FiberSense Continuous Glucose Monitoring (CGM) System has obta...
2026-06-17 17:06
5526
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is ev...
2026-06-17 16:06
4769
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026 European Hem...
2026-06-17 13:39
4617
RRS® HA Long Lasting awarded Best Injectable in Skin Revitalization at AMWC 2026, reinforcing Skin Tech Pharma Group's leadership in the Skin Builder category
BARCELONA, Spain, June 17, 2026 /PRNewswire/ -- Skin Tech Pharma Group proudly announces that its flagship injectable, RRS® HA LONG LASTING, has been recognized as Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, one of the most prestigious recogniti...
2026-06-17 08:00
3684
Ruixiang Silicone Releases Platinum-Cured Medical Silicone Tubing for Cardiac, Infusion, and Hemodialysis Device Manufacturers
USP Class VI, ISO 10993 biocompatibility evaluation, and ISO 13485:2016 quality system certification, manufactured at an FDA-registered facility DONGGUAN, China, June 16, 2026 /PRNewswire/ -- Dongguan Ruixiang Precision Silicone Products Co., Ltd. (Ruixiang Silicone) has released a platinum-cured...
2026-06-16 23:10
5569
Datasea Intelligent Technology Ltd. Announces CEO's Intention to Purchase Up to US$1.0 Million of the Company's Class A Ordinary Shares
BEIJING, June 16, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (Nasdaq: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Ms. Zhixin Liu, the Company's Chief Executive Officer and a benefici...
2026-06-16 21:30
6941
Waterdrop Inc. Reports First Quarter 2026 Unaudited Financial Results, Q1 Net Revenue Up 64.8% Year-over-Year
BEIJING, June 16, 2026 /PRNewswire/ -- On June 16, 2026, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with positive social impact, today announced its unaudited financial results for the first quarter ended March 31, 2026. In the first ...
2026-06-16 21:10
8642
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 318 media titles]
2026-07-24 12:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 293 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 290 media titles]
2026-07-24 16:25
Most Read
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
17377
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
2026-07-23 16:00
8472
Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
2026-07-20 11:00
8425
